The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia
Φόρτωση...
Ημερομηνία
Συγγραφείς
Florentin, M.
Liberopoulos, E. N.
Moutzouri, E.
Rizos, C. V.
Tselepis, A. D.
Elisaf, M. S.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Current Medical Research and Opinion
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Objective: To compare the effects of simvastatin alone versus simvastatin plus ezetimibe on small dense low-density lipoprotein cholesterol (sdLDL-C) concentration in subjects with primary hypercholesterolemia. Research design and methods: Patients with LDL-C levels above those recommended by the National Cholesterol Education Program Adult Treatment Panel III were randomized to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg as a fixed combination (n=50) daily. LDL particle size (estimated by electrophoresis), sdLDL-C levels, and lipid profile were blindly assessed at baseline and 3 months. Clinical trial registration: clinicaltrials.gov NCT00932620. Results: Both simvastatin 40 mg and simvastatin/ezetimibe 10/10 mg decreased total cholesterol (-31% and -36%, respectively), LDL-C (-43% and -49%, respectively), triglycerides (-17% and -19%, respectively), non-high-density lipoprotein cholesterol (non-HDL-C; -40% and -46%, respectively), large LDL-C (-40 and -44%, respectively) and sdLDL-C levels (-42% and -46%, respectively, all p<0.000 vs baseline) and increased LDL particle size (+0.5% and +0.7%, respectively, both p<0.05 vs baseline). The changes in total cholesterol, LDL-C and non-HDL-C were greater in the simvastatin/ezetimibe group (all p<0.05). Changes in triglycerides, large LDL-C, sdLDL-C levels and LDL particle size were similar in the two groups. In multivariate analysis, baseline sdLDL-C and triglyceride levels, but not the choice of treatment, were significantly and independently correlated with the changes in sdLDL-C levels. Conclusion: The combination of simvastatin 10 mg plus ezetimibe 10 mg is similarly effective to simvastatin 40 mg in improving sdLDL-C concentration and LDL particle size in subjects with primary hypercholesterolemia.
Περιγραφή
Λέξεις-κλειδιά
ezetimibe, low density lipoprotein particle size, simvastatin, small dense low density lipoprotein, intima-media thickness, c-reactive protein, ldl subfraction distribution, metabolic syndrome, familial hypercholesterolemia, randomized-trial, statin therapy, b metabolism, atorvastatin, ezetimibe/simvastatin
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
<Go to ISI>://000287322500021
http://informahealthcare.com/doi/abs/10.1185/03007995.2010.546394
http://informahealthcare.com/doi/abs/10.1185/03007995.2010.546394
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας